- Home
- DSGN vs HRTX Comparison
DSGN vs HRTX Comparison
Compare DSGN & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- HRTX
- Stock Information
- Founded
- DSGN 2017
- HRTX 1983
- Country
- DSGN United States
- HRTX United States
- Employees
- DSGN N/A
- HRTX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- HRTX Health Care
- Exchange
- DSGN Nasdaq
- HRTX Nasdaq
- Market Cap
- DSGN 208.9M
- HRTX 206.9M
- IPO Year
- DSGN 2021
- HRTX 1987
- Fundamental
- Price
- DSGN $7.14
- HRTX $1.27
- Analyst Decision
- DSGN
- HRTX Strong Buy
- Analyst Count
- DSGN 0
- HRTX 2
- Target Price
- DSGN N/A
- HRTX $4.50
- AVG Volume (30 Days)
- DSGN 189.7K
- HRTX 1.5M
- Earning Date
- DSGN 11-06-2025
- HRTX 11-11-2025
- Dividend Yield
- DSGN N/A
- HRTX N/A
- EPS Growth
- DSGN N/A
- HRTX N/A
- EPS
- DSGN N/A
- HRTX N/A
- Revenue
- DSGN N/A
- HRTX $149,694,000.00
- Revenue This Year
- DSGN N/A
- HRTX $10.62
- Revenue Next Year
- DSGN N/A
- HRTX $12.99
- P/E Ratio
- DSGN N/A
- HRTX N/A
- Revenue Growth
- DSGN N/A
- HRTX 9.78
- 52 Week Low
- DSGN $2.60
- HRTX $1.04
- 52 Week High
- DSGN $7.77
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- DSGN 65.47
- HRTX 44.34
- Support Level
- DSGN $5.98
- HRTX $1.18
- Resistance Level
- DSGN $6.61
- HRTX $1.31
- Average True Range (ATR)
- DSGN 0.38
- HRTX 0.05
- MACD
- DSGN 0.04
- HRTX 0.01
- Stochastic Oscillator
- DSGN 99.62
- HRTX 65.38
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.